Scalper1 News
On Wednesday, the morning after the annual Liver Meeting wrapped up in San Francisco, Wall Street analysts sifted through the implications of the data rolled out there for the vast hepatitis C market. Analysts saw continued dominance for Gilead Sciences (GILD) in genotype 1 of the hepatitis C virus (HCV), which accounts for the majority of cases. Gilead’s Harvoni, a combination of sofosbuvir (sold separately as Sovaldi) and ledipasvir, is already Scalper1 News
Scalper1 News